Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.
Mikael Dolsten, M.D., Ph.D., CSO and president, worldwide research, development and medical (WRDM), reveals the decade long turnaround of the Pfizer’s R&D innovation engine leading to what could be the company’s best ever pipeline.
Representatives from the National Kidney Foundation, Bayer, and digital health startup up, Bitome, share their views on what’s necessary to realize the promise of innovative digital health solutions toward treating the whole patient during an educational panel session at the 2019 BIO International Convention And Conference.
At the 2019 BIO Conference Chief Editor Rob Wright sat down with newly elected board-director chair, Jeremy Levin, DPhil, MB, BChir, CEO of Ovid Therapeutics to talk patent thickets and his role with BIO.
I was fearful that the Pfizer executive I was set to interview would be overly coached and not be transparent regarding his experiences. But that wasn’t the case at all.
Rob Wright takes issue with Peter Bach, M.D., and Mark Trusheim’s recommendation that the U.S. would be better served by abandoning continued biosimilar drug development.
Rob Wright digs into the “extreme teaming” work of Amy Edmondson, Novartis professor of leadership and management at Harvard, and Jean-Francois Harvey, assistant professor at HEC Montreal, drawing on the 2010 Chilean mining disaster as an example.
Many of us have good or even great ideas for a business, product or service, but only a handful follow through. Why?
Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.